Pneumococcal vaccines GRADE assessments

20-valent pneumococcal vaccine (Prevenar 20, 20vPCV) in adults

ATAGI recommendations

Coversheet on evidence assessment by ATAGI using the GRADE framework for 20vPCV in adults

Use of 20vPCV versus 13vPCV in adults aged >70 years without specific risk conditions

Use of 20vPCV versus 13vPCV + 23vPPV in adults aged >18 years with specific risk conditions

Use of 20vPCV versus 13vPCV in First Nations adults aged >50 years without specific risk conditions

GRADE assessment for 20vPCV

Compared to 13vPCV in adults aged >70 years without specific risk conditions

Compared to 13vPCV+23vPPV in adults aged >18 years with specific risk conditions

Compared to 13vPCV+23vPPV in First Nations adults aged >50 years without specific risk conditions

15-valent pneumococcal vaccine (Vaxnuevance, 15vPCV) in adults

ATAGI recommendations

Coversheet on evidence assessment by ATAGI using the GRADE framework for 15vPCV in adults

Use of 15vPCV versus 13vPCV in adults aged ≥70 years without specific risk factors

Use of 15vPCV + 23vPPV versus 13vPCV + 23vPPV in Indigenous adults aged ≥50 years without specific risk factors

Use of 15vPCV + 23vPPV versus 13vPCV + 23vPPV in adults aged ≥18 years with specific risk factors

GRADE assessment for 15vPCV

Compared to 13-valent pneumococcal vaccine (13vPCV) in adults aged ≥70 years without specific risk factors

Compared to 13vPCV + 23-valent pneumococcal polysaccharide vaccine (23vPPV) in Indigenous adults aged ≥50 years without specific risk factors

Compared to 13vPCV + 23vPPV in adults aged ≥18 years with specific risk factors

Note: These GRADE documents should be read as a supplement to Australian Immunisation Handbook recommendations.

View the pneumococcal disease chapter in the Australian Immunisation Handbook